Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNXP
Previous Symbol
CUSIPN/A
Phone212-980-9155
Debt
Debt-to-Equity RatioN/A
Current Ratio6.79
Quick Ratio7.23
Price-To-Earnings
Trailing P/E Ratio-0.18
Forward P/E Ratio-0.22
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.37 per share
Price / Book0.37
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-21,120,000.00
Net MarginsN/A
Return on Equity-130.30%
Return on Assets-115.43%
Miscellaneous
Employees14
Outstanding Shares10,020,000
Market Cap$5.82 million
OptionableOptionable
Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) posted its quarterly earnings results on Friday, November, 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.04. View Tonix Pharmaceuticals' Earnings History.
When is Tonix Pharmaceuticals' next earnings date?
What price target have analysts set for TNXP?
5 brokers have issued 1-year price targets for Tonix Pharmaceuticals' stock. Their predictions range from $1.00 to $8.00. On average, they anticipate Tonix Pharmaceuticals' share price to reach $4.50 in the next year. This suggests a possible upside of 782.4% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.
What is the consensus analysts' recommendation for Tonix Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tonix Pharmaceuticals.
Has Tonix Pharmaceuticals been receiving favorable news coverage?
News stories about TNXP stock have been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future.
Are investors shorting Tonix Pharmaceuticals?
Tonix Pharmaceuticals saw a increase in short interest in October. As of October 15th, there was short interest totalling 1,168,846 shares, an increase of 101.1% from the September 28th total of 581,273 shares. Based on an average trading volume of 1,564,105 shares, the days-to-cover ratio is presently 0.7 days. Approximately 12.5% of the company's stock are sold short. View Tonix Pharmaceuticals' Current Options Chain.
Who are some of Tonix Pharmaceuticals' key competitors?
Some companies that are related to Tonix Pharmaceuticals include Citius Pharmaceuticals (CTXR), Amarillo Biosciences (AMAR), Novelion Therapeutics (NVLN), Innovus Pharmaceuticals (INNV), Akari Therapeutics (AKTX), KITOV PHARMA LT/S (KTOV), Genprex (GNPX), NeuroVive Pharmaceutical (NEVPF), Edge Therapeutics (EDGE), ESSA Pharma (EPIX), Pulmatrix (PULM), Pain Therapeutics (PTIE), SUMMIT THERAPEU/S (SMMT), RegeneRx Biopharmaceuticals (RGRX) and Kaya (KAYS).
Who are Tonix Pharmaceuticals' key executives?
Tonix Pharmaceuticals' management team includes the folowing people:
- Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 60)
- Dr. Donald W. Landry, Co-Founder & Director (Age 63)
- Mr. Bradley Saenger, CFO & Treasurer (Age 44)
- Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 52)
- Mrs. Jessica Edgar Morris, Chief Operating Officer
How do I buy shares of Tonix Pharmaceuticals?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals' stock price today?
One share of TNXP stock can currently be purchased for approximately $0.51.
How big of a company is Tonix Pharmaceuticals?
Tonix Pharmaceuticals has a market capitalization of $5.82 million. The company earns $-21,120,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe.
What is Tonix Pharmaceuticals' official website?
How can I contact Tonix Pharmaceuticals?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVE. - SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]
MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
